SUMMARY
New generation of antithrombotic drugs nowadays frequently replaces classic anticoagulants (heparin and coumarines).

Direct oral anticoagulants (DOAC) induce direct thrombin (activated coagulation factor II) or factor Xa (activated coagulation factor X) inhibition. These drugs offer pharmacologic advantages, such as consistent and predictable anticoagulation, rapid on-set of action, short half-life, high bioavailability, good safety profile, and low risk of clinically relevant drug interactions. Furthermore, there is no need for a routine laboratory monitoring of these agents. This review article discusses the effect of DOAC on routine coagulation assays.

Key words: direct oral anticoagulants, coagulation tests, dabigatran, rivaroxaban, apixaban, edoxaban.

Lek Obz, 2020, 69(12):  452-456

Ingrid Škorňová 1, Tomáš Bolek 2, Martin Schnierer 3,  Lucia Stančiaková, Ján Staško 1, Monika Brunclíková 1, Ján Hudeček 1, Matej Samoš 2, Peter Kubisz 1

1 Národné centrum hemostázy a trombózy,  Klinika hematológie a transfuziológie JLF UK a UNM, Martin
2 I. Interná klinika JLF UK a UNM, Martin
3 Interná klinika – Gastroenterologická JLF UK a UNM, Martin

CITE:
Škorňová I., Bolek T., Schnierer M.,  Stančiaková L., Staško J., Brunclíková M., Hudeček J., Samoš M., Kubisz P: Direct oral anticoagulants and their impact on coagulation tests. Lek Obz, 2020, 69(12):  452-456